Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zometa for prevention of bone metastases in high-risk prostate cancer
2004-001786-18Phase 3Completed
- Sponsor
- European Association of Urology
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in prostate cancer (PCa) (2 arms), sponsored by European Association of Urology. Primary endpoint: Proportion of patients with at least one bone metastasis after 48 months of treatment. Started May 2007; status: completed.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-001786-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001786-18.